Physician profile
Traci Hartsfield
NPI 1407986540
$2,708.89
in general payments reported to CMS, 2019-2025
23 companies · $863 in 2025
The $863 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.47 · 2023: $736 · 2024: $1,025 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $658.11 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.15 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $254.11 | 2023-2025 | Verquvo |
| Amgen INC. | $233.59 | 2023-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $225.76 | 2024-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $199.97 | 2022-2024 | Xarelto |
| Edwards Lifesciences Corporation | $172.25 | 2024-2025 | Sapien 3 Ultra Resilia, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $160.87 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.70 | 2025 | |
| Sanofi-Aventis U.S. LLC | $46.73 | 2023-2024 | |
| Boston Scientific Corporation | $39.94 | 2025 | Bodyguardian |
| Azurity Pharmaceuticals, INC. | $39.04 | 2023 | Edarbi, Horizant |
| Glaxosmithkline, LLC. | $37.85 | 2025 | Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $34.17 | 2024 | Arcalyst |
| Cvrx, INC. | $31.51 | 2023 | Barostim Neo System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.08 | 2024 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $22.31 | 2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $20.02 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $18.31 | 2024 | Livalo |
| Heartflow, INC. | $15.75 | 2024 | |
| Scpharmaceuticals INC. | $13.61 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.87 | 2023 | Lifevest |
| Vivaquant INC, Dba Rhythm Express | $8.19 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Hartsfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.